Ruxolitinib is an inhibitor of JAK1 and JAK2 approved for the treatment of myelofibrosis.
Ruxolitinib is een remmer van JAK1 en JAK2 goedgekeurd voor de behandeling van myelofibrose.
| Front | An inhibitor of JAK1 and JAK2 approved for treatment of myelofibrosis |
|---|---|
| Back | ruxolitinib |
Learn with these flashcards. Click next, previous, or up to navigate to more flashcards for this subject.
Next card: Cell-based immunotherapy treat prostate cancer combined prostatic acid
Previous card: Chimeric antibody cd20 eliminate b cells treatment non-hodgkins
Up to card list: Janeway's Immunobiology 9th Edition Concept Flash Card